Lundbeck to present positive pipeline data at American Academy of Neurology Annual Meeting

H. Lundbeck A/S Denmark

[phone]

[phone]

Palle Holm Olesen

Vice President, Investor Relations

[e-mail]

[phone]

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has approximately 5,500 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

References:

1.  American Academy of Neurology Annual Meeting 2025. Safety, Tolerability, and Efficacy of Bexicaserin in a Cohort of Participants with Developmental and Epileptic Encephalopathies: Interim Results of a Phase 1b/2a PACIFIC Study Open-Label Extension.

2.  Sheffer I, et al. Epilepsia. 2025 Feb 27.doi: 10.1111/epi.18265.

3.  Kaye R, et al. Efficacy and safety of bexicaserin (LP352) in adolescent and adult participants with developmental and epileptic encephalopathies: Results of the phase 1b/2a PACIFIC study. Presented at the Annual Meeting of the American Academy of Neurology; April 13-18, 2024

4.  Ailani J, et al. Poster Presentation. American Academy of Neurology Annual Meeting 2025.

5.  Argoff C, et al. Poster presentation. American Academy of Neurology Annual Meeting 2025.

6.  Starling A, et al. Poster Presentation. American Academy of Neurology Annual Meeting 2025.

CONTACT: 
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
[phone]
[e-mail]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h--lundbeck-a-s/r/lundbeck-to-present-positive-pipeline-data-at-american-academy-of-neurology--aan--annual-meeting,c4131034

The following files are available for download:

https://mb.cision.com/Main/18215/4131034/3368357.pdf

Lundbeck AAN_ Final

 

View original content:https://www.prnewswire.co.uk/news-releases/lundbeck-to-present-positive-pipeline-data-at-american-academy-of-neurology-aan-annual-meeting-302420645.html